The current predominant therapeutic paradigm is based on maximizing drug-receptor occupancy to achieve clinical benefit. This strategy, however, generally requires excessive drug concentrations to ensure sufficient occupancy, often leading to adverse side effects. Here, we describe major improvements to the proteolysis targeting chimeras (PROTACs) method, a chemical knockdown strategy in which a heterobifunctional molecule recruits a specific protein target to an E3 ubiquitin ligase, resulting in the target's ubiquitination and degradation. These compounds behave catalytically in their ability to induce the ubiquitination of super-stoichiometric quantities of proteins, providing efficacy that is not limited by equilibrium occupancy. We present two PROTACs that are capable of specifically reducing protein levels by >90% at nanomolar concentrations. In addition, mouse studies indicate that they provide broad tissue distribution and knockdown of the targeted protein in tumor xenografts. Together, these data demonstrate a protein knockdown system combining many of the favorable properties of small-molecule agents with the potent protein knockdown of RNAi and CRISPR.
Your institute does not have access to this article
Open Access articles citing this article.
Journal of Hematology & Oncology Open Access 15 July 2022
Nature Communications Open Access 01 June 2022
Medicinal Chemistry Research Open Access 12 May 2022
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Adjei, A.A. What is the right dose? The elusive optimal biologic dose in phase I clinical trials. J. Clin. Oncol. 24, 4054–4055 (2006).
Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004).
Bumcrot, D., Manoharan, M., Koteliansky, V. & Sah, D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2, 711–719 (2006).
Tokatlian, T. & Segura, T. siRNA applications in nanomedicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2, 305–315 (2010).
Buckley, D.L. & Crews, C.M. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. Angew. Chem. Int. Edn. Engl. 53, 2312–2330 (2014).
Sakamoto, K.M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 98, 8554–8559 (2001).
Schneekloth, A.R., Pucheault, M., Tae, H.S. & Crews, C.M. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg. Med. Chem. Lett. 18, 5904–5908 (2008).
Schneekloth, J.S. Jr. et al. Chemical genetic control of protein levels: selective in vivo targeted degradation. J. Am. Chem. Soc. 126, 3748–3754 (2004).
Hines, J., Gough, J.D., Corson, T.W. & Crews, C.M. Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs. Proc. Natl. Acad. Sci. USA 110, 8942–8947 (2013).
Min, J.H. et al. Structure of an HIF-1α -pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886–1889 (2002).
Hon, W.C. et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417, 975–978 (2002).
Rodriguez-Gonzalez, A. et al. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene 27, 7201–7211 (2008).
Puppala, D., Lee, H., Kim, K.B. & Swanson, H.I. Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention. Mol. Pharmacol. 73, 1064–1071 (2008).
Itoh, Y. et al. Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist. Bioorg. Med. Chem. Lett. 22, 4453–4457 (2012).
Okuhira, K. et al. Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells. Cancer Sci. 104, 1492–1498 (2013).
Sekine, K. et al. Small molecules destabilize cIAP1 by activating auto-ubiquitylation. J. Biol. Chem. 283, 8961–8968 (2008).
Buckley, D.L. et al. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1alpha interaction. J. Am. Chem. Soc. 134, 4465–4468 (2012).
Crews, C.M. et al. Compounds and methods for the inhibition of vcb e3 ubiquitin ligase. Patent PCT/US2013/021141 (2013).
Buckley, D.L. et al. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1alpha. Angew. Chem. Int. Edn Engl. 51, 11463–11467 (2012).
Eichner, L.J. & Giguere, V. Estrogen related receptors (ERRs): a new dawn in transcriptional control of mitochondrial gene networks. Mitochondrion 11, 544–552 (2011).
Patch, R.J. et al. Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents. J. Med. Chem. 54, 788–808 (2011).
Humphries, F., Yang, S., Wang, B. & Moynagh, P.N. RIP kinases: key decision makers in cell death and innate immunity. Cell Death Differ. 22, 225–236 (2015).
Miceli-Richard, C. et al. CARD15 mutations in Blau syndrome. Nat. Genet. 29, 19–20 (2001).
Kanazawa, N. et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 105, 1195–1197 (2005).
Meng, L. et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA 96, 10403–10408 (1999).
Windheim, M., Lang, C., Peggie, M., Plater, L.A. & Cohen, P. Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochem. J. 404, 179–190 (2007).
Schwanhäusser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337–342 (2011).
Douglass, E.F. Jr., Miller, C.J., Sparer, G., Shapiro, H. & Spiegel, D.A. A comprehensive mathematical model for three-body binding equilibria. J. Am. Chem. Soc. 135, 6092–6099 (2013).
Kamura, T. et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. USA 97, 10430–10435 (2000).
Iwai, K. et al. Identification of the von Hippel–Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. USA 96, 12436–12441 (1999).
Lanvin, O., Bianco, S., Kersual, N., Chalbos, D. & Vanacker, J.M. Potentiation of ICI182,780 (Fulvestrant)-induced estrogen receptor-alpha degradation by the estrogen receptor-related receptor-alpha inverse agonist XCT790. J. Biol. Chem. 282, 28328–28334 (2007).
Lee, J., Udugamasooriya, D.G., Lim, H.S. & Kodadek, T. Potent and selective photo-inactivation of proteins with peptoid-ruthenium conjugates. Nat. Chem. Biol. 6, 258–260 (2010).
Jewell, U.R. Induction of HIF-1a in response to hypoxia is instantaneous. FASEB J. 15, 1312–1314 (2001).
Guo, Y. et al. Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif. Nature 505, 229–233 (2014).
Spiegel, D.A. A call to ARMs: the promise of immunomodulatory small molecules. Expert Rev. Clin. Pharmacol. 6, 223–225 (2013).
Clark, M.A. et al. Design, synthesis and selection of DNA-encoded small-molecule libraries. Nat. Chem. Biol. 5, 647–654 (2009).
Noblin, D.J. et al. A HaloTag-based small molecule microarray screening methodology with increased sensitivity and multiplex capabilities. ACS Chem. Biol. 7, 2055–2063 (2012).
Bradner, J.E. et al. A robust small-molecule microarray platform for screening cell lysates. Chem. Biol. 13, 493–504 (2006).
Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007).
Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255–265 (2011).
Becher, I. et al. Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes. ACS Chem. Biol. 9, 1736–1746 (2014).
Bergamini, G. et al. A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation. Nat. Chem. Biol. 8, 576–582 (2012).
Werner, T. et al. High-resolution enabled TMT 8-plexing. Anal. Chem. 84, 7188–7194 (2012).
Kruse, U. et al. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 25, 89–100 (2011).
Werner, T. et al. Ion coalescence of neutron encoded TMT 10-plex reporter ions. Anal. Chem. 86, 3594–3601 (2014).
Savitski, M.M. et al. Delayed fragmentation and optimized isolation width settings for improvement of protein identification and accuracy of isobaric mass tag quantification on Orbitrap-type mass spectrometers. Anal. Chem. 83, 8959–8967 (2011).
Savitski, M.M. et al. Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays. J. Am. Soc. Mass Spectrom. 21, 1668–1679 (2010).
Savitski, M.M. et al. Measuring and managing ratio compression for accurate iTRAQ/TMT quantification. J. Proteome Res. 12, 3586–3598 (2013).
Sharma, K. et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741–744 (2009).
Grossmann, J. et al. Implementation and evaluation of relative and absolute quantification in shotgun proteomics with label-free methods. J. Proteomics 73, 1740–1746 (2010).
Silva, J.C., Gorenstein, M.V., Li, G.-Z., Vissers, J.P.C. & Geromanos, S.J. Absolute quantification of proteins by LCMSE: a virtue of parallel ms acquisition. Mol. Cell. Proteomics 5, 144–156 (2006).
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. & Golani, I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 125, 279–284 (2001).
We thank K. Mueller and D. Poeckel for cell culture support; S. Melchert, E. Stonehouse, A. Lachert, J. Cox, M. Leveridge, C. Pancevac and M. Jundt for biochemistry and sample preparation support; M. Boesche, T. Rudi, M. Kloes-Hudak and K. Kammerer for mass spectrometry support; and S. Gade for data analysis support. This research was partially supported by US National Institutes of Health grants AI084140, T32GM067543 and T32GM007223.
A.M., I.E.D.S., S.C., A.M., N.Z., P.G., S.S., G.B., M.F.-S., M.B., L.N.C., B.J.V., K.F., L.K., P.S.C., J.D.H. and I.C. are employees of GlaxoSmithKline. D.A.G., R.R.W. and J.J.F. are employees of Arvinas, LLC. C.M.C. is a shareholder/consultant for Arvinas, LLC and consults for Canaan Partners.
Supplementary Results, Supplementary Figures 1–10 and Supplementary Note. (PDF 11920 kb)
Relative abundance of proteins immunoprecipitated with the active or inactive VHL ligands (XLSX 46 kb)
Results summary for expression proteomics (XLSX 568 kb)
Proteomic analysis of RIPK2 phosphorylation sites (XLSX 12 kb)
Results summary for ternary complex formation (XLSX 414 kb)
Results summary for Kinobead competition binding experiments (XLSX 11061 kb)
About this article
Cite this article
Bondeson, D., Mares, A., Smith, I. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol 11, 611–617 (2015). https://doi.org/10.1038/nchembio.1858
Molecular Cancer (2022)
Journal of Hematology & Oncology (2022)
Nature Reviews Clinical Oncology (2022)
Nature Reviews Drug Discovery (2022)
Nature Biotechnology (2022)